 |
|
|
| |
ABT-450/R/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE RATES REGARDLESS OF BASELINE CHARACTERISTICS: POOLED ANALYSES OF THE SAPPHIRE-I AND SAPPHIRE-II STUDIES
|
| |
| |
Reported by Jules Levin
IDWeek 2014
Philadelphia, PA
October 8-12, 2014
EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
HIV/HCV Coinfection: http://www.natap.org/2014/HCV/090314_06.htm.......
ICAAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 - (09/08/14)
Jordan J. Feld, Ola Weiland, Rui T. Marinho, Heiner Wedemeyer, Ira M. Jacobson, Donald M. Jensen, Tarek Hassanein, Victor de Ledinghen, Moisés Diago, Lorenzo Magenta, Robert J. De Knegt, Bo Fu, Eoin Coakley, Fernando Tatsch, Graham R. Foster
|
| |
|
|
|
|
|
